Logo

Merck to Acquire Alydia Health for ~$240M on Behalf of its Planned Spinoff of Organon

Share this

M&A

Merck to Acquire Alydia Health for ~$240M on Behalf of its Planned Spinoff of Organon

Shots:

  • Organon to acquire Alydia Health for up to $240M including $215M up front out of which $50 will be paid prior to the spinoff of Organon- $165 will be paid on the closure of the acquisition while remaining will be paid upon achievement of the milestones. Alydia will also receive ~$25M as a contingent milestone
  • The acquisition is expected to close after the completion of the spinoff of Organon from Merck- expected in Q2’21
  • The acquisition will foster the delivery of the Jada System to prevent maternal morbidity and mortality caused by PPH or abnormal postpartum uterine bleeding

  Ref: Business Wire | Image: Merck

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions